Cargando…

A novel staging model to classify oesophageal squamous cell carcinoma patients in China

BACKGROUND: Oesophageal squamous cell carcinoma (ESCC) is the predominant subtype of oesophageal carcinoma in China, with the overall 5-year survival rate of <10%. The current tumour-node-metastasis (TNM) staging system has become so complex that it is not easy to use in the life expectancy asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, H, Zhang, H, Xie, J, Chen, B, Wen, C, Guo, X, Zhao, Q, Wu, Z, Shen, J, Wu, J, Xu, X, Li, E, Xu, L, Wang, X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992487/
https://www.ncbi.nlm.nih.gov/pubmed/24569468
http://dx.doi.org/10.1038/bjc.2014.101
_version_ 1782312578342453248
author Tan, H
Zhang, H
Xie, J
Chen, B
Wen, C
Guo, X
Zhao, Q
Wu, Z
Shen, J
Wu, J
Xu, X
Li, E
Xu, L
Wang, X
author_facet Tan, H
Zhang, H
Xie, J
Chen, B
Wen, C
Guo, X
Zhao, Q
Wu, Z
Shen, J
Wu, J
Xu, X
Li, E
Xu, L
Wang, X
author_sort Tan, H
collection PubMed
description BACKGROUND: Oesophageal squamous cell carcinoma (ESCC) is the predominant subtype of oesophageal carcinoma in China, with the overall 5-year survival rate of <10%. The current tumour-node-metastasis (TNM) staging system has become so complex that it is not easy to use in the life expectancy assessment. We aim to combine clinical variables and biomarkers to develop and validate a relative simple and reliable model, named the FENSAM, for ESCC prognosis. METHODS: To build the FENSAM, we analysed 22 potential prognostic factors from 461 patients, including 9 biomarkers (Ezrin, Fascin, desmocollin 2 (DSC2), pFascin, activating transcription factor 3 (ATF3), connective-tissue growth factor (CTGF), neutrophil gelatinase-associated lipocalin (NGAL), NGAL receptor (NGALR), and cysteine-rich angiogenic protein 61 (CYR61)) and other 13 clinical variables. We selected significant factors associated with survival of ESCC patients, and used them to build our FENSAM model. We then obtained the hazard risk score of the model to classify ESCC patients. In addition, we validated the model in an independent cohort of 290 patients from the same hospital. The predictive performance of the model was assessed by the Area under the Receiver Operating Characteristic Curve (AUC) and Kaplan–Meier survival analysis. RESULTS: We found six markers significantly associated with survival of ESCC patients (Ezrin, Fascin, ATF3, surgery extent, N-stage, and M-stage). They were combined to create a novel four-stage FENSAM model for patients' classification. FENSAM possessed a high classification precision similar to the TNM staging system, but with a much simpler model. The efficiency of FENSAM was evaluated by different quantiles of AUC and the results of survival analysis. The validation result demonstrated the potential of the FENSAM model to improve classification accuracy for ESCC patients CONCLUSIONS: FENSAM provides an alternative classifier for ESCC patients with a high classification precision using a simple model.
format Online
Article
Text
id pubmed-3992487
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-39924872015-04-15 A novel staging model to classify oesophageal squamous cell carcinoma patients in China Tan, H Zhang, H Xie, J Chen, B Wen, C Guo, X Zhao, Q Wu, Z Shen, J Wu, J Xu, X Li, E Xu, L Wang, X Br J Cancer Molecular Diagnostics BACKGROUND: Oesophageal squamous cell carcinoma (ESCC) is the predominant subtype of oesophageal carcinoma in China, with the overall 5-year survival rate of <10%. The current tumour-node-metastasis (TNM) staging system has become so complex that it is not easy to use in the life expectancy assessment. We aim to combine clinical variables and biomarkers to develop and validate a relative simple and reliable model, named the FENSAM, for ESCC prognosis. METHODS: To build the FENSAM, we analysed 22 potential prognostic factors from 461 patients, including 9 biomarkers (Ezrin, Fascin, desmocollin 2 (DSC2), pFascin, activating transcription factor 3 (ATF3), connective-tissue growth factor (CTGF), neutrophil gelatinase-associated lipocalin (NGAL), NGAL receptor (NGALR), and cysteine-rich angiogenic protein 61 (CYR61)) and other 13 clinical variables. We selected significant factors associated with survival of ESCC patients, and used them to build our FENSAM model. We then obtained the hazard risk score of the model to classify ESCC patients. In addition, we validated the model in an independent cohort of 290 patients from the same hospital. The predictive performance of the model was assessed by the Area under the Receiver Operating Characteristic Curve (AUC) and Kaplan–Meier survival analysis. RESULTS: We found six markers significantly associated with survival of ESCC patients (Ezrin, Fascin, ATF3, surgery extent, N-stage, and M-stage). They were combined to create a novel four-stage FENSAM model for patients' classification. FENSAM possessed a high classification precision similar to the TNM staging system, but with a much simpler model. The efficiency of FENSAM was evaluated by different quantiles of AUC and the results of survival analysis. The validation result demonstrated the potential of the FENSAM model to improve classification accuracy for ESCC patients CONCLUSIONS: FENSAM provides an alternative classifier for ESCC patients with a high classification precision using a simple model. Nature Publishing Group 2014-04-15 2014-02-25 /pmc/articles/PMC3992487/ /pubmed/24569468 http://dx.doi.org/10.1038/bjc.2014.101 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Tan, H
Zhang, H
Xie, J
Chen, B
Wen, C
Guo, X
Zhao, Q
Wu, Z
Shen, J
Wu, J
Xu, X
Li, E
Xu, L
Wang, X
A novel staging model to classify oesophageal squamous cell carcinoma patients in China
title A novel staging model to classify oesophageal squamous cell carcinoma patients in China
title_full A novel staging model to classify oesophageal squamous cell carcinoma patients in China
title_fullStr A novel staging model to classify oesophageal squamous cell carcinoma patients in China
title_full_unstemmed A novel staging model to classify oesophageal squamous cell carcinoma patients in China
title_short A novel staging model to classify oesophageal squamous cell carcinoma patients in China
title_sort novel staging model to classify oesophageal squamous cell carcinoma patients in china
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992487/
https://www.ncbi.nlm.nih.gov/pubmed/24569468
http://dx.doi.org/10.1038/bjc.2014.101
work_keys_str_mv AT tanh anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT zhangh anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT xiej anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT chenb anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wenc anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT guox anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT zhaoq anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wuz anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT shenj anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wuj anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT xux anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT lie anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT xul anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wangx anovelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT tanh novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT zhangh novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT xiej novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT chenb novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wenc novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT guox novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT zhaoq novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wuz novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT shenj novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wuj novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT xux novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT lie novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT xul novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina
AT wangx novelstagingmodeltoclassifyoesophagealsquamouscellcarcinomapatientsinchina